Olivier Bogillot

Independant Director, member of the Audit Committee and Member of the Ethics, Quality and CSR Committee

Date of appointment: General Meeting of 14 May 2025
End of term of office: General Meeting convene to approve the financial statements for the year ending 31 December 2027

With a PhD in Economics from the University of Lyon I, a Master’s degree in Health Economics and Public Health and a degree in Molecular Biology and Physiology, Olivier Bogillot has held senior positions at Merck KGaA, Amgen and Bristol-Myers Squibb, mainly in market access in France and Europe. 

In 2009, he took on a Director role within the Île-de-France Regional Health Agency, reporting to Claude Evin, before joining the Presidency of the French Republic in 2011 as advisor for health, dependency policies and social policies. 

In 2015, he joined Sanofi, where he held various positions including Executive Chief Global Policy Officer, Chief of Staff to the Chief Executive Officer, Chairman of Sanofi France and then Head of North America General Medicines. 

Olivier Bogillot has sat on the Board of Directors of Leem (professional organization of pharmaceutical companies), chaired the French federation of healthindustries and the Strategic Committee of the Sector (SCF) of the Health Industries and Technologies attached to the French Prime Minister. He was also a member of the Medef board and co-chair of the Medef Social Protection Commission.

Also read

  • About us

    With 63,000 employees in six European countries, Clariane is meeting the major challenge of taking care of each person’s humanity in times of vulnerabilty through its three activities.

  • Values

    Trust, responsibility, initiative: our three values are at the heart of our commitment and guide our actions on a daily basis.

  • Strategy

    With “At your side”, its new corporate project, Clariane confirms its strategic shift from old age to fragility.